LZLeida Zhang

Leida Zhang

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Leida Zhang has a total of 86 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Comprehensive characterization of SLC41A3 identifies it as an immune-related prognostic biomarker and therapeutic target in hepatocellular carcinoma

    by Biyan Gong, Dunfu Cao, Shidong Hu, Xiangyi Zhou, Leida Zhang, Fengsheng Dai, Jianheng Peng

    Background: Hepatocellular carcinoma (HCC) represents a highly aggressive cancer associated with substantial patient mortality. Members of the solute carrier (SLC) protein family have been implicated in facilitating tumor development and progression. However, the specific functions and relevance of SLC41A3 in the context of HCC pathogenesis are not well defined. Methods: Differentially expressed SLC genes were screened from the TCGA-LIHC cohort. Prognostic analysis identified independent prognostic factors. Diagnostic and prognostic models were constructed using machine learning and LASSO regression. Multi-omics analysis was employed to assess the expression characteristics, clinical relevance, spatial heterogeneity, and correlation with immune infiltration of SLC41A3. The biological function of SLC41A3 was validated through in vitro proliferation, colony formation, migration, and invasion assays, as well as an in vivo xenograft tumor model. Results: Sixty-nine SLC genes were differentially expressed in HCC, with eight identified as independent prognostic factors, including SLC41A3. The constructed diagnostic and prognostic models based on these genes demonstrated robust performance. SLC41A3 was highlighted as the most contributory feature in the diagnostic model. High expression of SLC41A3 was significantly associated with advanced clinicopathological features, poorer patient survival, specific spatial expression patterns, and altered immune cell infiltration in the tumor microenvironment. Functionally, knockdown of SLC41A3 significantly inhibited HCC cell proliferation, migration, invasion in vitro , and suppressed tumor growth in vivo . Conclusion: This study identifies SLC41A3 as a novel prognostic biomarker and a promoter of HCC progression, with its function potentially linked to immune microenvironment modulation, suggesting its promise as a therapeutic target for HCC.


  • Open Access

    Endoscopic treatment and outcome-oriented classification of biliary strictures after liver transplantation: a multicenter retrospective cohort study

    by Zeliang Xu, Danqing Liu, Mingxing Xia, Ji Xuan, Xiubi Yin, Di Jiang, Jingya Kuang, Chengcheng Christine Zhang, Yanjiao Ou, Wei Liu, et al.

    Background: To date, there is no consensus classification of post-liver transplantation biliary strictures (LTBS), particularly for guiding treatment. This study aimed to propose a novel classification system for guiding treatment choice and prognosis prediction. Methods: Patients with biliary stricture (BS) from three centers were analyzed retrospectively. Combined with the latest guidelines, a location-based classification system was developed that included the following categories: extrahepatic BS (type I), perihilar BS (type II), and intrahepatic BS (type III). Stent treatment choices were assessed, and a fully covered self-expandable metal stent (FCMS) with plastic biliary stent (PBS) implantation method for type II was introduced. Treatment characteristics and outcomes among the three types were also analyzed. Results: According to initial successful endoscopic cholangiography, 96 patients were classified into three types: I (43.8%), II (32.3%) and III (24.0%). For type I patients, fewer treatment sessions (P=0.02) and lower costs (P=0.04) were noted for FCMS compared to PBS. Compared to PBS implantation alone, FCMS + PBS had a similar advantage as the type II group. During the follow-up period, 69.0% of type I, 61.3% of type II and 34.7% of type III patients achieved stent-free success, and type III patients demonstrated the worst treatment effects (P=0.03). The stent duration, number of endoscopic procedures increased from type I to type III patients (P=0.04). Conclusions: This location-based classification provides insights for clinical treatment recommendations, offering a typological basis for establishing a standardized treatment protocol for BS after liver transplantation.

  • Open Access

    Machine Learning Model for Predicting Biliary Complications After Liver Transplantation

    by Feng Hu, Yuancheng Li, Hongfei Zeng, Renhua Ju, Di Jiang, Leida Zhang, Jun Li, Xingchao Liu, Guangyi Liu, Chengcheng Zhang

    INTRODUCTION: The risk factors of biliary complications (BCs) after liver transplantation are not comprehensively determined. BCs also vary in times of onset. Machine learning (ML) can reveal regularities based on large-scale data to make predictions and have demonstrated good performance in liver transplantation. However, whether ML can be an efficient tool for BC prediction was not determined. METHODS: Five hundred seventeen patients from 2 centers were enrolled. Patients were randomly divided into training and validation sets at 3:1 ratio. K-fold cross-validation and the synthetic minority oversampling technique were used to debug the models, which were evaluated by receiver operating characteristic curves. SHapley Additive exPlanation values and Sankey diagrams were applied to visualize the results. Seven ML algorithms were administrated to build models for BCs prediction at 3, 6, and 12 months. RESULTS: Among all the models, support vector machine produced the highest area under curve values in predicting BCs (3-month = 0.916; 6-month = 0.892; 12-month = 0.885). According to the analysis of support vector machine, the 3-month risk factors of BCs and corresponding SHapley Additive exPlanation value ranges were donor age (−0.13, 0.21), Model for End-Stage Liver Disease score (−0.15, 0.18), neoplastic disease (−0.14, 0.28), diabetes (−0.12, 0.27), hypertension (−0.13, 0.21), and intraoperative blood transfusion (−0.09, 0.25), whereas 6-month factors were recipient age (−0.14, 0.16), donor body mass index (−0.10, 0.13), recipient body mass index (−0.13, 0.23), and diabetes (−0.12, 0.43). The 12-month risk factors were recipient age (−0.14, 0.19), diabetes (−0.13, 0.25), and basiliximab (−0.16, 0.24). The Sankey diagram enabled clear visualization of the contribution of individual risk factors to the model in different times of BCs onset. DISCUSSION: The ML algorithm was able to identify risk factors of BCs in all postoperative periods and this supplied insights in patient management.


  • Open Access

    A Brief Model Evaluated Outcomes After Liver Transplantation Based on the Matching of Donor Graft and Recipient

    by Yuancheng Li, Xingchao Liu, Chengcheng Zhang, Ran Tao, Bi Pan, Wei Liu, Di Jiang, Feng Hu, Zeliang Xu, Dehong Tan, et al.

    INTRODUCTION: A precise model for predicting outcomes is needed to guide perioperative management. With the development of the liver transplantation (LT) discipline, previous models may become inappropriate or noncomprehensive. Thus, we aimed to develop a novel model integrating variables from donors and recipients for quick assessment of transplant outcomes. METHODS: The risk model was based on Cox regression in a randomly selected derivation cohort and verified in a validation cohort. Perioperative data and overall survival were compared between stratifications grouped by X-tile. Receiver-operating characteristic curve and decision curve analysis were used to compare the models. Violin and raincloud plots were generated to present post-LT complications distributed in different stratifications. RESULTS: Overall, 528 patients receiving LT from 2 centers were included with 2/3 in the derivation cohort and 1/3 in the validation cohort. Cox regression analysis showed that cold ischemia time (CIT) (P = 0.012) and Model for End-Stage Liver Disease (MELD) (P = 0.007) score were predictors of survival. After comparison with the logarithmic models, the primitive algorithms of CIT and MELD were defined as the CIT-MELD Index (CMI). CMI was stratified by X-tile (grade 1 ≤1.06, 1.06 < grade 2 ≤ 1.87, grade 3 >1.87). In both cohorts, CMI performed better in calculating transplant outcomes than the balance of risk score, including perioperative incidents and prevalence of complications. DISCUSSION: The model integrating variables from graft donors and recipients made the prediction more accurate and available. CMI provided new insight into outcome evaluation and risk factor management of LT.

  • Adequate cumulative exposure to tacrolimus and low tacrolimus variability decrease the incidence of biliary complications after liver transplantation

    by Bi Pan, Yuancheng Li, Xiaojun Wang, Yanjiao Ou, Gang Heng, Xingchao Liu, Di Jiang, Wei Liu, Yixian Huang, Feng Hu, et al.


  • Living-Donor Liver Transplant for Patients With End-stage Liver Disease

    by Chengcheng Zhang, Yanjiao Ou, Leida Zhang

    To the Editor The recent article by Jackson et al1 raised our interest. This nationwide study showed that recipients with Model for End-stage Liver Disease incorporating sodium levels (MELD-Na) score of 11 or higher benefited from living-donor liver transplant (LDLT), while the rest were not judging by 1-year survival benefit. The authors stated that this result challenged MELD scores more than 15 as the cutoff value2 and suggested nationwide superior acceptance of LDLT to deceased donors for patients with MELD-Na scores of 11 or higher. However, we have the following concerns.

  • A Novel Bioscaffold Material-based Transplantable Liver Reconstruction

    by Deyu Hu, Zhenyu Wu, Jiejuan Lai, Min Yan, Quanyu Chen, Leida Zhang, Hongyu Zhang, Lianhua Bai

    End-stage liver disease (ESLD) is an important cause of death worldwide and the interest in tissue engineering with decellularization/recellularization approach is currently promising one for liver regeneration. The decellularized scaffold generated from normal whole liver (nDLS) preserves the original orchestral structure and bioactive chemicals of the liver, and has the potential to create a de novo liver that is fit for transplantation after recellularization. As the lack of active ECM of the nDLS impacting seed cell survival and hemocompatibility are key hurdles for functional liver reconstruction, a novel approach needs to be formulated. This chapter provides a comprehensive outlook on how these drawbacks can be turned into the current challenges in the field, and put forward a few potentially viable options to address these challenges, mainly focusing on a novel decellularized liver scaffold (rDLS)-based liver engineering strategy. We speculate that the primary concepts necessary for advantages of the rDLS in liver reconstructing processes as compared to the nDLS. Additionally, the criteria for major obstacles in using rDLS are covered in detail.

  • Open Access

    Safety analysis of COVID-19 vaccines in liver transplant recipients: a two-center study

    by Rui Tang, Chao Li, Guangdong Wu, Xuan Tong, Lihan Yu, Huayuan Hao, Rui Liao, Yucheng Hou, Jun Li, Wenping Zhao, et al.

    Safety analysis of COVID-19 vaccines in liver transplant recipients: a two-center study Rui Tang, Chao Li, Guangdong Wu, Xuan Tong, Lihan Yu, Huayuan Hao, Rui Liao, Yucheng Hou, Jun Li, Wenping Zhao, Tieyan Fan, Leida Zhang, Qian Lu


  • Open Access

    Comment to pure laparoscopic living donor liver transplantation: Dreams come true

    by Chengcheng Zhang, Yanjiao Ou, Wei Liu, Leida Zhang


  • Open Access

    Low preoperative prealbumin predicts the prevalence of complications following liver transplantation

    by Yuancheng Li, Xingchao Liu, Yan Jiang, Kun Wan, Wei Liu, Yanjiao Ou, Jie Bai, Yuemei You, Feng Hu, Zeliang Xu, et al.

    Background: As a nutritional index, preoperative serum prealbumin highly correlates with surgical complications. However, the correlation between preoperative prealbumin and postoperative complications remains unclear in liver transplantation (LT). Methods: A total of 191 patients who underwent LT between 2015 and 2019 were included in the retrospective analysis. According to a cut-off value calculated from a receiver operating characteristic (ROC) curve, the patients were divided into normal and low preoperative prealbumin groups. Univariable and multivariable logistic regression analyses were used to identify independent risk factors for postoperative complications. In addition, patients were divided into subgroups by Model for End-stage Liver Disease (MELD) score, and the association between preoperative prealbumin and postoperative complications was also assessed in each group. Results: A total of 111 (58.1%) patients were included in the low prealbumin group based on a cut-off value of 120 mg/L. The area under the ROC curve (AUC) was 0.754 (95% confidence interval [CI] 0.678–0.832). Low prealbumin (95% CI 1.51–12.8, P = 0.007) was identified as a predictor for postoperative complications based on multivariable regression. In the low and normal prealbumin groups, the prevalence rates of postoperative complications were 27.5% and 8.0% (P = 0.003) in the MELD score ≤ 15 subgroup and 53.3% and 20.0% (P = 0.197) in the MELD score > 15 subgroup, respectively. Conclusions: Preoperative prealbumin was associated with postoperative complications in LT, and preoperative nutritional support benefitted postoperative recovery, especially for patients with low MELD scores.